Bandaríkin - enska - NLM (National Library of Medicine)

remedyrepack inc. - atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i) - atropine sulfate injection, usp, may be given parenterally as a pre-anesthetic medication in surgical patients to reduce salivation and bronchial secretions. it may also be used to suppress vagal activity associated with the use of halogenated hydrocarbons during inhalation anesthesia and reflex excitation arising from mechanical stimulation during surgery. the antispasmodic action of atropine is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. for ureteral and biliary colic, atropine concomitantly with morphine may be indicated. atropine relaxes the upper gi tract and colon during hypotonic radiography. in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases, large doses of atropine relieve the muscarine-like symptoms and some of the central nervous system manifestations. it is also used as an antidote for mushroom poisoning due to muscarine in certain species such as amanita muscaria . atropine sulfate

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - atropine sulfate monohydrate 0,1 mg/ml - eq. atropine 0,083 mg/ml - solution for injection in pre-filled syringe - 0,1 mg/ml - atropine sulfate monohydrate 0.1 mg/ml - atropine

Belgía - enska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - atropine sulfate monohydrate 0,1 mg/ml - eq. atropine 0,083 mg/ml - solution for injection in pre-filled syringe - 0,1 mg/ml - atropine sulfate monohydrate 0.1 mg/ml - atropine

Bandaríkin - enska - NLM (National Library of Medicine)

rafa laboratories, ltd. - atropine (unii: 7c0697dr9i) (atropine - unii:7c0697dr9i) - atropine 1 mg in 0.7 ml - atropine is indicated for the treatment of poisoning by susceptible organophosphorus nerve agents having anticholinesterase activity as well as organophosphorus or carbamate insecticides in adults and pediatric patients weighing more than 41 kg (90 pounds). none. pregnancy risk summary atropine readily crosses the placental barrier and enters fetal circulation. there are no adequate data on the developmental risk associated with the use of atropine in pregnant women. adequate animal reproduction studies have not been conducted with atropine. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. lactation risk summary atropine has been reported to be excreted in human milk. there are no data on the effects of atropine on the breastfed infant or the effects of the drug on milk production.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

scigen australia pty ltd - somatropin, quantity: 3.3 mg/ml - injection - excipient ingredients: mannitol; benzyl alcohol; poloxamer; water for injections; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate dihydrate; sodium hydroxide; phosphoric acid - scitropin a is intended for long term treatment of children (above three years of age with growth disturbance due to insufficient secretion of pituitary growth hormone; growth disturbance associated with gonadal dysgenesis (turner's syndrome); & growth disturbance associated with chronic renal insufficiency.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

max health limited - atropine sulfate 0.06%{relative} - solution for injection - 600 mcg/ml - active: atropine sulfate 0.06%{relative} excipient: sodium chloride - atropine may be given as a pre-anaesthetic medication to inhibit excessive salivary and bronchial secretions and to diminish the risk of vagal inhibition of the heart. the use of atropine as an antisialagogue is rarely necessary since the introduction of halothane and similar anaesthetics in place of ether anaesthesia. atropine may be administered concurrently with anticholinesterase agents (e.g. neostigmine, physostigmine) to block the adverse muscarinic effects when they are used after surgery to terminate curarisation. it is also used concomitantly with a cholinesterase reactivator (e.g. pralidoxime) to reverse muscarinic effects associated with toxic exposure to anticholinesterase compounds (e.g. organophosphate pesticides). atropine may be used in conjunction with morphine or other agents for the relief of biliary or renal colic. it may be used in the management of patients with acute myocardial infarction and sinus bradycardia who have associated hypotension and increased ventricular irritability.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - somatropin, quantity: 8 mg/ml - injection, solution - excipient ingredients: phenol; sucrose; citric acid; poloxamer; water for injections; sodium hydroxide - saizen is indicated for:,1. treatment of growth failure in children due to human growth hormone deficiency.,2. treatment of growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis.,3. replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defind by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfill the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.,4. treatment of growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - somatropin, quantity: 8 mg/ml - injection, solution - excipient ingredients: sucrose; poloxamer; sodium hydroxide; water for injections; citric acid; phenol - saizen is indicated for:,1. treatment of growth failure in children due to human growth hormone deficiency.,2. treatment of growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis.,3. replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defind by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfill the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.,4. treatment of growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - somatropin, quantity: 5.83 mg/ml - injection, solution - excipient ingredients: poloxamer; sodium hydroxide; sucrose; citric acid; phenol; water for injections - saizen is indicated for:,1. treatment of growth failure in children due to human growth hormone deficiency.,2. treatment of growth failure in girls with gonadal dysgenesis (turner syndrome), confirmed by chromosomal analysis.,3. replacement therapy in adults with pronounced growth hormone deficiency as diagnosed in 2 different dynamic tests for growth hormone deficiency and defind by peak gh concentrations of less than 2.5 nanogram/ml. adults must also fulfill the following criteria: childhood onset: patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with saizen is started. adult onset: patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.,4. treatment of growth disturbance (growth retardation) in pre-pubertal children due to chronic renal insufficiency (cri).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

scigen australia pty ltd - somatropin, quantity: 6.67 mg/ml - injection, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; monobasic sodium phosphate dihydrate; poloxamer; phenol; glycine; phosphoric acid; sodium hydroxide; water for injections - omnitrope is intended for the long term treatment of children (above three years of age) with, growth disturbance due to insufficient secretion of pituatary growth hormone, growth disturbance associated with gonadal dysgenesis (turner syndrome), growth disturbance associated with chronic renal insufficiency.